In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 165253-29-2, name is 3-(Bromomethyl)tetrahydrofuran, introducing its new discovery. Application In Synthesis of 3-(Bromomethyl)tetrahydrofuran
The present invention provides substituted heteroaryl compound and its composition and use. The compounds of formula (I) compound of formula or type (I) a compound represented by stereo isomers, tautomers, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or its prodrug. The invention also provides a pharmaceutical composition, said pharmaceutical composition can be modulating protein kinase, particularly Aurora kinase and JAK kinase activity, for the prevention, treatment, treatment and reduce protein kinase, particularly Aurora kinase and JAK kinase activity mediated diseases or disorders. (by machine translation)
We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 165253-29-2, and how the biochemistry of the body works.Application In Synthesis of 3-(Bromomethyl)tetrahydrofuran
Reference：
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem